Cantor Fitzgerald Analysts Lower Earnings Estimates for EYPT

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) - Cantor Fitzgerald decreased their FY2025 earnings estimates for EyePoint Pharmaceuticals in a research note issued to investors on Thursday, March 6th. Cantor Fitzgerald analyst J. Kim now anticipates that the company will earn ($2.96) per share for the year, down from their previous forecast of ($2.49). The consensus estimate for EyePoint Pharmaceuticals' current full-year earnings is ($2.13) per share.

EyePoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last announced its quarterly earnings results on Wednesday, March 5th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.54) by ($0.10). EyePoint Pharmaceuticals had a negative return on equity of 43.01% and a negative net margin of 226.57%. The business had revenue of $11.60 million during the quarter, compared to the consensus estimate of $11.02 million.

Other equities research analysts have also issued reports about the stock. HC Wainwright restated a "buy" rating and set a $22.00 price objective on shares of EyePoint Pharmaceuticals in a report on Thursday, March 6th. Citigroup started coverage on EyePoint Pharmaceuticals in a research note on Tuesday, January 7th. They set a "buy" rating and a $33.00 price objective on the stock. Finally, Chardan Capital reiterated a "buy" rating and set a $33.00 price target on shares of EyePoint Pharmaceuticals in a report on Thursday, March 6th. One research analyst has rated the stock with a sell rating and nine have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $26.63.

Remove Ads

EyePoint Pharmaceuticals Stock Performance

EYPT stock traded down $0.46 during mid-day trading on Monday, hitting $6.88. 304,130 shares of the company were exchanged, compared to its average volume of 835,008. EyePoint Pharmaceuticals has a 1-year low of $5.54 and a 1-year high of $23.97. The firm's 50 day simple moving average is $7.25 and its 200 day simple moving average is $8.42. The firm has a market cap of $472.51 million, a P/E ratio of -3.46 and a beta of 1.41.

Institutional Investors Weigh In On EyePoint Pharmaceuticals

Large investors have recently bought and sold shares of the company. Legal & General Group Plc boosted its position in shares of EyePoint Pharmaceuticals by 4.4% during the 4th quarter. Legal & General Group Plc now owns 46,263 shares of the company's stock worth $345,000 after acquiring an additional 1,932 shares in the last quarter. Summit Investment Advisors Inc. grew its holdings in shares of EyePoint Pharmaceuticals by 39.6% during the 4th quarter. Summit Investment Advisors Inc. now owns 6,838 shares of the company's stock valued at $51,000 after purchasing an additional 1,940 shares during the last quarter. Invesco Ltd. increased its position in EyePoint Pharmaceuticals by 16.1% during the 4th quarter. Invesco Ltd. now owns 15,657 shares of the company's stock worth $117,000 after purchasing an additional 2,177 shares in the last quarter. Teacher Retirement System of Texas lifted its stake in EyePoint Pharmaceuticals by 22.4% in the 4th quarter. Teacher Retirement System of Texas now owns 15,192 shares of the company's stock valued at $113,000 after purchasing an additional 2,782 shares during the last quarter. Finally, Swiss National Bank lifted its stake in EyePoint Pharmaceuticals by 3.5% in the 4th quarter. Swiss National Bank now owns 100,000 shares of the company's stock valued at $745,000 after purchasing an additional 3,400 shares during the last quarter. 99.41% of the stock is currently owned by institutional investors and hedge funds.

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.